ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Krista Davis Sells 1,000 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total value of $60,000.00. Following the transaction, the senior vice president now directly owns 49,059 shares in the company, valued at approximately $2,943,540. The trade was a 2.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

ANI Pharmaceuticals Price Performance

Shares of ANI Pharmaceuticals stock opened at $56.56 on Friday. ANI Pharmaceuticals, Inc. has a 52-week low of $51.24 and a 52-week high of $70.81. The stock’s 50-day simple moving average is $58.04 and its 200 day simple moving average is $60.36. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm had revenue of $148.30 million for the quarter, compared to analysts’ expectations of $144.37 million. During the same period in the prior year, the business posted $1.05 earnings per share. The company’s revenue was up 12.5% on a year-over-year basis. On average, equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Texas Permanent School Fund Corp increased its position in shares of ANI Pharmaceuticals by 1.3% during the second quarter. Texas Permanent School Fund Corp now owns 13,372 shares of the specialty pharmaceutical company’s stock valued at $852,000 after buying an additional 178 shares during the period. Louisiana State Employees Retirement System grew its holdings in shares of ANI Pharmaceuticals by 2.7% during the second quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock worth $490,000 after purchasing an additional 200 shares in the last quarter. Arizona State Retirement System grew its holdings in shares of ANI Pharmaceuticals by 4.7% during the second quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock worth $299,000 after purchasing an additional 211 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in shares of ANI Pharmaceuticals by 2.3% during the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after purchasing an additional 299 shares in the last quarter. Finally, New York State Teachers Retirement System grew its holdings in shares of ANI Pharmaceuticals by 1.7% during the third quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock worth $1,439,000 after purchasing an additional 394 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on ANIP shares. Raymond James lifted their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 18th. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday. HC Wainwright reiterated a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Piper Sandler started coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They set an “overweight” rating and a $68.00 target price on the stock. Finally, Truist Financial lifted their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research note on Tuesday, October 22nd. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $77.71.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.